Novel piperidine derivatives. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine derivatives. 1990

H Sugimoto, and Y Tsuchiya, and H Sugumi, and K Higurashi, and N Karibe, and Y Iimura, and A Sasaki, and Y Kawakami, and T Nakamura, and S Araki
Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan.

A series of 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine derivatives was synthesized and evaluated for anti-acetylcholinesterase (anti-AChE) activity. Substituting the benzamide with a bulky moiety in the para position led to a substantial increase in activity. Introduction of an akyl or phenyl group at the nitrogen atom of benzamide dramatically enhanced the activity. The basic quality of the nitrogen atom of piperidine appears to play an important role in the increased activity, since the N-benzoylpiperidine derivative was almost inactive. We found that 1-benzyl-4-[2-(N-[4'-(benzylsulfonyl) benzoyl]-N-methylamino]ethyl]piperidine hydrochloride (21) (IC50 = 0.56 nM) is one of the most potent inhibitors of acetylcholinesterase. Compound 21 showed an affinity 18,000 times greater for AChE than for BuChE. At a dose of 3 mg/kg, 21 produced a marked and significant increase in acetylcholine (ACh) content in the cerebral vortex and hippocampus of rats. Compound 21 was chosen for advanced development as an antidementia agent.

UI MeSH Term Description Entries
D007202 Indicators and Reagents Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499) Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D010830 Physostigmine A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Eserine
D010880 Piperidines A family of hexahydropyridines.
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002091 Butyrylcholinesterase An aspect of cholinesterase (EC 3.1.1.8). Pseudocholinesterase,Benzoylcholinesterase,Butyrylthiocholinesterase
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D000110 Acetylcholinesterase An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. Acetylcholine Hydrolase,Acetylthiocholinesterase,Hydrolase, Acetylcholine

Related Publications

H Sugimoto, and Y Tsuchiya, and H Sugumi, and K Higurashi, and N Karibe, and Y Iimura, and A Sasaki, and Y Kawakami, and T Nakamura, and S Araki
September 2011, Bioorganic & medicinal chemistry,
H Sugimoto, and Y Tsuchiya, and H Sugumi, and K Higurashi, and N Karibe, and Y Iimura, and A Sasaki, and Y Kawakami, and T Nakamura, and S Araki
March 2001, Life sciences,
H Sugimoto, and Y Tsuchiya, and H Sugumi, and K Higurashi, and N Karibe, and Y Iimura, and A Sasaki, and Y Kawakami, and T Nakamura, and S Araki
June 2007, Archiv der Pharmazie,
H Sugimoto, and Y Tsuchiya, and H Sugumi, and K Higurashi, and N Karibe, and Y Iimura, and A Sasaki, and Y Kawakami, and T Nakamura, and S Araki
July 1990, Journal of medicinal chemistry,
H Sugimoto, and Y Tsuchiya, and H Sugumi, and K Higurashi, and N Karibe, and Y Iimura, and A Sasaki, and Y Kawakami, and T Nakamura, and S Araki
June 2007, Archiv der Pharmazie,
H Sugimoto, and Y Tsuchiya, and H Sugumi, and K Higurashi, and N Karibe, and Y Iimura, and A Sasaki, and Y Kawakami, and T Nakamura, and S Araki
November 1995, Journal of medicinal chemistry,
H Sugimoto, and Y Tsuchiya, and H Sugumi, and K Higurashi, and N Karibe, and Y Iimura, and A Sasaki, and Y Kawakami, and T Nakamura, and S Araki
December 2011, Acta crystallographica. Section E, Structure reports online,
H Sugimoto, and Y Tsuchiya, and H Sugumi, and K Higurashi, and N Karibe, and Y Iimura, and A Sasaki, and Y Kawakami, and T Nakamura, and S Araki
October 2013, Iranian journal of basic medical sciences,
H Sugimoto, and Y Tsuchiya, and H Sugumi, and K Higurashi, and N Karibe, and Y Iimura, and A Sasaki, and Y Kawakami, and T Nakamura, and S Araki
January 2011, Chemical & pharmaceutical bulletin,
H Sugimoto, and Y Tsuchiya, and H Sugumi, and K Higurashi, and N Karibe, and Y Iimura, and A Sasaki, and Y Kawakami, and T Nakamura, and S Araki
January 1999, Acta poloniae pharmaceutica,
Copied contents to your clipboard!